




PHARMACEUTICAL 2022

Skye Bioscience Inc.
Rank 346 of 466





PHARMACEUTICAL 2022

Skye Bioscience Inc.
Rank 346 of 466

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Skye Bioscience Inc. is the variable Net Income, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 23%, being 55% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	9,612
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,912
Liabilities, Non-Current	79
Other Assets	155
Other Compr. Net Income	0
Other Expenses	2.1
Other Liabilities	0
Other Net Income	-672
Other Revenues	0
Property and Equipment	88
Research and Development	2,931
Selling, General and Administrative Expense	4,916

Output Variable	Value in 1000 USD
Assets	9,855
Liabilities	3,991
Expenses	7,850
Revenues	0
Stockholders Equity	5,864
Net Income	-8,522
Comprehensive Net Income	-8,522
Economic Capital Ratio	23%